Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
PR Newswire•02/11/2026•16:50 ET
0
Key Highlights
- ➤Total revenue $1.123B, up 41% year-over-year
- ➤INGREZZA sales $801M, up 17% year-over-year
- ➤INGREZZA 2026 sales guidance raised to $2.9B-$2.925B
- ➤Non-GAAP EPS $3.29, up from $2.17 year-over-year
- ➤CRENESSITY sales $211M and VYKAT XR sales $107M
Expert Statements
Kyle W. Gano, Chief Executive Officer of Neurocrine Biosciences
“Our third quarter performance marks another important milestone in Neurocrine's evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines.”
Kyle W. Gano, Chief Executive Officer of Neurocrine Biosciences
“This continued growth reinforces the strength of our strategy and expands our capacity to invest in innovation, advance our pipeline and build an enduring biopharmaceutical company.”
Kyle W. Gano, Chief Executive Officer of Neurocrine Biosciences
“Looking ahead to 2027, we see meaningful opportunities for continued growth across INGREZZA, CRENESSITY and VYKAT XR, alongside multiple important clinical milestones, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia.”
Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results PR Newswire
Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion
Get started
Create a free account to read the full story.